| Expression pattern: |
UP |
| Associated gene: |
SLC1A5 |
| Associated microRNA: |
miR-137 |
| Biological function: |
circ-LDLRAD3 acts as an oncogene in NSCLC; it promotes cell proliferation and invasion, inhibits apoptosis, and supports malignant phenotypes including mobility and EMT-associated changes. |
| Molecular mechanism: |
circ-LDLRAD3 functions as a competing endogenous RNA that sponges miR-137, thereby relieving miR-137-mediated repression of SLC1A5 and increasing SLC1A5 expression in NSCLC cells. |
| Biological pathway or process: |
ceRNA regulation (other); proliferation (promotes); invasion (promotes); apoptosis (inhibits); EMT (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; TUNEL; Western Blot |
| Clinical significance: |
High circ-LDLRAD3 expression is associated with high-grade TNM stage and lymphatic metastasis in NSCLC patients, suggesting potential diagnostic and therapeutic relevance. |
| Description: |
circ-LDLRAD3 is up-regulated in NSCLC tissues and cell lines and is associated with advanced TNM stage and lymphatic metastasis. Functionally, it promotes NSCLC cell proliferation and invasion while suppressing apoptosis. Mechanistically, circ-LDLRAD3 sponges miR-137 to up-regulate SLC1A5, forming a circ-LDLRAD3/miR-137/SLC1A5 oncogenic axis. |
| Confidence score: |
0.7181 |